Kidney Cancer Weekly

April 13, 2026

Videos

Peer-to-Peer Clinical Conversations

CYTOSHRINK: Evaluating SBRT to the Primary Tumor in De Novo Advanced RCC - Aly-Khan Lalani

Aly-Khan Lalani

Aly-Khan Lalani presents CYTOSHRINK, randomizing 67 de novo advanced renal cell carcinoma patients two-to-one to stereotactic body radiation plus nivolumab/ipilimumab versus nivolumab/ipilimumab alone.

Phase I Trial Explores Formulation of CBM588 Probiotic in Advanced RCC - Miguel Zugman

Miguel Zugman presents phase I dose escalation results testing refrigerated capsule formulation of CBM588 probiotic with nivolumab/ipilimumab in 12 first-line metastatic clear cell renal cell carcinoma patients.

Beyond the Abstracts

Durable Responses to Immune Checkpoint Inhibitor-Based Regimens for Metastatic Clear Cell Renal Cell Carcinoma Stratified by IMDC Risk Groups: A Pooled Analysis of Four Randomized Phase 3 Trials - Beyond the Abstract

[99mTc]Tc-Sestamibi SPECT/CT for the Diagnosis of Kidney Tumours: A Multi-Centre Feasibility Study (MULTI-MIBI Study) - Beyond the Abstract

Conference Coverage

EAU 2026: Adjuvant Pembrolizumab + Belzutifan for Clear Cell RCC: Primary and Exploratory Efficacy Outcomes from the Phase 3 LITESPARK-022 Study

EAU 2026: Impact of Girentuximab Based Radionuclide Imaging in Patients with RCC on Virtual Tumor Board Decision Making: An Interim Analysis

ASCO GU 2026: Imaging for Renal Cell Carcinoma: Current State of the Art

ASCO GU 2026: Biomarker Analysis from the Phase 2 LITESPARK-013 Study of Two Different Belzutifan Doses in Participants with Advanced Clear Cell RCC

ASCO GU 2026: Fruquintinib + Serplulimab as First Line Therapy in Metastatic or Unresectable Non-Clear Cell RCC: Updated Efficacy and Safety Data from a Multicenter, Single-Arm, Phase II Trial

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Oncologic Outcomes of Microwave Ablation of Biopsy-Proven cT1a Renal Cell Carcinomas.

Belzutifan Efficacy in Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma Versus Natural History Control Arm.

Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.

Safety, Feasibility and Prognostic Analysis of Surgical Treatment for High-Complexity Renal Tumours (RENAL Score ≥ 10): A Summary of Experience With Robotic Technology Applications.

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.

SET1B Drives Sustained HIF activity and Disease Progression in Clear Cell Renal Cell Carcinoma.

Evaluating Nephrectomy Outcomes in Regional Victoria: A Single-Centre Cohort Study.

Concurrent Tissue and Circulating Tumor DNA analysis in Renal Cell Carcinoma: Insights from a Multimodal Database.

Laboratory paraneoplastic syndrome resolution is associated with reduced recurrence and improved survival in non-metastatic renal cell carcinoma.

Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium.

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC